TICKERNERD
Menu
INVAINVAHealthcare · Biotechnology

INVA Stock Forecast: Innoviva, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$21
+2.12% on the day

The 4 Wall Street analysts covering Innoviva, Inc. hold a median 12-month price target of $38 — +79.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.5B
Ticker Nerd rank
85 / 100
Median analyst target
$38
Analysts covering
4
Total return, dividends reinvested
1W
+3.3%
1M
−2.5%
YTD
+6.0%
1Y
+1.5%
From 52W high
−12.6%
From 52W low
+27.1%
$17
$24
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INVA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Innoviva, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
85 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
100
Volatility
100
Quality
89
Growth
81
Issuance
76
Momentum
60
Revisions
53
Size
39
Accruals
14

Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (14): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INVA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INVA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40$45$50Oct 25Jan 26Apr 26Jul 26INVAHigh $46Median $38Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
3 Buy0 Hold1 Sell
Low $18Median $38High $46

The green dot is the last close — the median target sits +79.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026Cantor FitzgeraldMaintainsOverweight$36 → $34
22 June 2026BTIGMaintainsBuy—
22 June 2026BTIGMaintainsBuy$42
1 June 2026HC Wainwright & Co.ReiteratesBuy—
26 May 2026BTIGReiteratesBuy—
7 May 2026BTIGMaintainsBuy—
26 Feb 2026BTIGReiteratesBuy—
17 Feb 2026BTIGInitiatesBuy—
16 Dec 2025HC Wainwright & Co.MaintainsBuy—
6 Nov 2025Cantor FitzgeraldMaintainsOverweight—
30 Sept 2025Goldman SachsInitiatesSell—
11 Aug 2025HC Wainwright & Co.MaintainsBuy—
11 Aug 2025OppenheimerInitiatesOutperform—
14 July 2025HC Wainwright & Co.InitiatesBuy—
11 July 2025Cantor FitzgeraldInitiatesOverweight—
7 Mar 2025ScotiabankInitiatesSector Outperform—
1 Aug 2024Cantor FitzgeraldReiteratesOverweight—
30 July 2024Cantor FitzgeraldReiteratesOverweight—
20 June 2024Cantor FitzgeraldReiteratesOverweight—
18 June 2024Cantor FitzgeraldInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INVA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

INVA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−6.1%
Analysts raising
1
Analysts cutting
1
Fundamentals

Innoviva, Inc. (INVA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
4.8×

Cheaper than 66% of US stocks

Price / sales
3.5×

Cheaper than 37% of US stocks

Price / book
1.2×

Cheaper than 66% of US stocks

EV / EBITDA
6.6×

Cheaper than 50% of US stocks

Growth & margins
Revenue growth (YoY)
19.3%

Higher than 69% of US stocks

Earnings growth (YoY)
19.3%

Higher than 58% of US stocks

Gross margin
75.8%

Higher than 88% of US stocks

Operating margin
43.3%

Higher than 93% of US stocks

Net margin
81.2%

Higher than 98% of US stocks

Returns & dividend
Return on equity
36.7%

Higher than 90% of US stocks

Return on assets
6.9%

Higher than 85% of US stocks

Dividend yield
4.7%

Higher than 82% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

INVA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
INVAInnoviva, Inc.$1.5B
85
BCAXBicara Therapeutics, Inc.$1.6B
48
JBIOJade Biosciences, Inc.$1.6B
26
XERSXeris Biopharma Holdings, Inc.$1.6B
85
VIRVir Biotechnology, Inc.$1.6B
93
ABSIAbsci Corp.$1.6B
34
LBRXLB Pharmaceuticals, Inc.$1.5B
7

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Innoviva, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INVA news & analysis

Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Business Wire · 11 Aug 2026positive

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., announced that three of its infectious disease therapies—XACDURO, ZEVTERA, and NUZOLVENCE—have been named finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year that an Innoviva Specialty Therapeutics product has been recognised as a finalist.

Why it matters — The recognition of three Innoviva therapies as finalists for a prestigious pharmaceutical award highlights the strength and continued recognition of the company's infectious disease portfolio.

Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic

Seeking Alpha · 6 Aug 2026positive

A Seeking Alpha article discusses Innoviva's transition from a royalty-based business to a diversified healthcare company, noting that GSK royalty revenue is under pressure while newer therapeutic products are ramping up to close the gap. The author assigns a buy rating with probability-weighted and base-case fair value estimates above the current price.

Why it matters — A INVA watcher would care because the piece addresses the key risk of declining GSK royalties and whether new commercial products can offset that revenue decline.

Innoviva (INVA) Q2 Earnings and Revenues Top Estimates

Zacks Investment Research · 6 Aug 2026neutral

Innoviva reported Q2 earnings of $0.59 per share, which beat the Zacks Consensus Estimate of $0.56 per share, though this was down from $0.77 per share in the same quarter a year ago.

Why it matters — The earnings beat indicates Innoviva exceeded analyst expectations for the quarter, which INVA watchers would note when assessing the company's recent performance.

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

Business Wire · 5 Aug 2026positive

Innoviva, Inc. reported its financial results for the second quarter ended June 30, 2026, and highlighted select corporate progress and achievements across its royalties portfolio, critical care and infectious disease platform (Innoviva Specialty Therapeutics), and strategic healthcare investments.

Why it matters — An INVA watcher would care because the report provides an update on the company's financial performance and evidence of recent corporate progress and achievements.

Supernus Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 3 Aug 2026neutral

Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a proposed all-stock, tax-free merger of equals. The combined company would be a central nervous system-focused biopharmaceutical firm with approximately $2.2 billion in pro forma trailing 12-month net revenue as of June 30, 2026.

Why it matters — As a fellow biopharmaceutical company, Innoviva investors may watch this merger for signals of broader industry consolidation trends in the CNS space.

FAQ

Frequently asked questions about INVA stock

What is the INVA stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Innoviva, Inc. have a median 12-month price target of $38, with estimates ranging from $18 to $46. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INVA stock a buy right now?

Of the 4 analysts covering Innoviva, Inc., 3 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Innoviva, Inc. 85 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INVA?

As at 15 Aug 2026, Innoviva, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).

Will INVA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +79.3% from the last close, and Ticker Nerd's factor model ranks Innoviva, Inc. 85 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INVA stock forecast for 2030?

No analyst covering Innoviva, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INVA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $46 over the next 12 months.

How has INVA stock performed over the past year?

Innoviva, Inc. returned +1.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Innoviva, Inc. do?

Innoviva Inc. is an innovative pharmaceutical company, focusing primarily on managing royalty portfolios that originate from collaborations with external partners.

What is the latest news on INVA?

The most recent item we track (Business Wire, 11 Aug 2026): "Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award". Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., announced that three of its infectious disease therapies—XACDURO, ZEVTERA, and NUZOLVENCE—have been named finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year that an Innoviva Specialty Therapeutics product has been recognised as a finalist.

Company

About Innoviva, Inc.

Innoviva Inc. is an innovative pharmaceutical company, focusing primarily on managing royalty portfolios that originate from collaborations with external partners. This asset plays a significant role in the healthcare sector, specifically within the pharmaceuticals and biotechnology industries. The company is involved in the development and commercialization of products in the respiratory disease space, notably co-developing medicines that address chronic obstructive pulmonary disease (COPD) and asthma. Innoviva Inc.'s strategy revolves around optimizing the value of its intellectual property through strategic partnerships with major pharmaceutical players. By leveraging its royalty agreements, the company aims to maximize returns while minimizing direct operational risks associated with drug development. Founded in 1996 as Theravance, the firm transitioned to Innoviva Inc., illustrating a shift towards focusing on royalty management and investment in biopharmaceutical innovations. This positioning allows Innoviva to have a significant presence in the market, impacting the treatment approaches in the respiratory disease segment and contributing to the broader pharmaceutical and healthcare ecosystem."}

CEO Mr. Pavel Raifeld C.F.A. · 159 employees · United States · https://www.inva.com